<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Cell biology : Cellular types : Animal cells :" exact="Blood" post="cells : White blood cells: NK cells : Biology"/>
 <result pre="cells : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Covid 19 : Biology and"/>
 <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Covid 19 : Biology and life"/>
 <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Covid 19 : Biology and life sciences :"/>
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Coronaviruses : SARS coronavirus: SARS CoV 2"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Coronaviruses : SARS coronavirus: SARS CoV 2"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Coronaviruses : SARS coronavirus: SARS CoV 2"/>
 <result pre="Innate Immune System: Cytokines : Biology and Life Sciences :" exact="Developmental" post="Biology : Molecular Development: Cytokines : Medicine and Health"/>
 <result pre="Development: Cytokines : Medicine and Health Sciences : Oncology :" exact="Cancer" post="Treatment: Cytokine Therapy : Biology and Life Sciences :"/>
 <result pre=": Cell Biology : Cellular Types : Animal Cells :" exact="Blood" post="Cells : White Blood Cells: T Cells : Biology"/>
 <result pre="Cellular Types : Animal Cells : Blood Cells : White" exact="Blood" post="Cells: T Cells : Biology and Life Sciences :"/>
 <result pre="Cellular Types : Animal Cells : Immune Cells : White" exact="Blood" post="Cells: T Cells : Biology and Life Sciences :"/>
 <result pre="and Life Sciences : Immunology : Immune Cells : White" exact="Blood" post="Cells: T Cells : Medicine and Health Sciences :"/>
 <result pre="and Health Sciences : Immunology : Immune Cells : White" exact="Blood" post="Cells: T Cells Friends or foes? The knowns and"/>
 <result pre="Boston, Massachusetts, United States of America[2], Ragon Institute of Massachusetts" exact="General" post="Hospital, MIT, and Harvard, Cambridge, Massachusetts, United States of"/>
 <result pre="in this global fight against COVID-19. Unfortunately, there is somewhat" exact="limited" post="knowledge of the role of NK cells in SARS-CoV-2"/>
 <result pre="limited knowledge of the role of NK cells in SARS-CoV-2" exact="infections" post="and even in the related SARS-CoV-1 and MERS-CoV infections."/>
 <result pre="NK cell therapeutic options already exist in the treatment of" exact="tumor" post="and other viral diseases and could be repurposed against"/>
 <result pre="options already exist in the treatment of tumor and other" exact="viral" post="diseases and could be repurposed against COVID-19. In this"/>
 <result pre="Fc receptor gamma chain; IFNÎ³, interferon-gamma; NK, natural killer; TNFÎ±," exact="tumor" post="necrosis factor alpha. NK cells in COVID-19â€&quot;infected people exhibit"/>
 <result pre="tumor necrosis factor alpha. NK cells in COVID-19â€&quot;infected people exhibit" exact="lower" post="expression of activating receptors including NKp30, NKG2D, NKG2C, CD16,"/>
 <result pre="injury. Several NK cellâ€&quot;based therapeutics currently in development against COVID-19" exact="infection" post="employ different strategies, including inducing NK cell activation, inhibiting"/>
 <result pre="of NK cells against infected cells for early clearance of" exact="viral" post="infected cells, and prevent tissue injury. COVID-19 virology and"/>
 <result pre="MERS, has helped piece together the clinical course of COVID-19" exact="infection" post="[5,6], which Mason and colleagues [7] describe as 3"/>
 <result pre="SARS-CoV-1, primarily spreads through the intranasal route, in which the" exact="viral" post="spike protein binds to the receptor angiotensin converting enzyme"/>
 <result pre="2 (ACE2) that is expressed on many cells of the" exact="respiratory" post="tract [8]. With a mean incubation period of 5.1"/>
 <result pre="incubation period of 5.1 days, the first stage of COVID-19" exact="infection" post="is characterized by local viral replication and shedding in"/>
 <result pre="the first stage of COVID-19 infection is characterized by local" exact="viral" post="replication and shedding in the upper respiratory tract even"/>
 <result pre="is characterized by local viral replication and shedding in the" exact="upper" post="respiratory tract even in the absence of clinical symptoms,"/>
 <result pre="characterized by local viral replication and shedding in the upper" exact="respiratory" post="tract even in the absence of clinical symptoms, thus"/>
 <result pre="and shedding in the upper respiratory tract even in the" exact="absence of" post="clinical symptoms, thus making asymptomatic patients infectious and further"/>
 <result pre="in the absence of clinical symptoms, thus making asymptomatic patients" exact="infectious" post="and further facilitating easy spread of infection. In the"/>
 <result pre="In the second stage of infection, the virus spreads to" exact="lower" post="respiratory tract at which time a robust innate immune"/>
 <result pre="the second stage of infection, the virus spreads to lower" exact="respiratory" post="tract at which time a robust innate immune response"/>
 <result pre="immune response is elicited and is also marked by clinical" exact="disease" post="of COVID-19. The most common symptoms of COVID-19 include"/>
 <result pre="fever, cough, and fatigue and, additionally, headache, dyspnea, hemoptysis, and" exact="diarrhea" post="[9,10]. High blood neutrophil count particularly neutrophil to lymphocyte"/>
 <result pre="fibroblast growth factor 2 (FGF2), granulocyte colony-stimulating factor (G-CSF), granulocyte" exact="monocyte" post="colony stimulation factor (GM-CSF), interferon (IFN)-Î³, IP-10/CXCL10, monocyte chemoattractant"/>
 <result pre="(G-CSF), granulocyte monocyte colony stimulation factor (GM-CSF), interferon (IFN)-Î³, IP-10/CXCL10," exact="monocyte" post="chemoattractant protein (MCP)-1, monocyte inhibitory protein (MIP)-1Î±, MIP-1Î², platelet"/>
 <result pre="stimulation factor (GM-CSF), interferon (IFN)-Î³, IP-10/CXCL10, monocyte chemoattractant protein (MCP)-1," exact="monocyte" post="inhibitory protein (MIP)-1Î±, MIP-1Î², platelet derived growth factor subunit"/>
 <result pre="protein (MIP)-1Î±, MIP-1Î², platelet derived growth factor subunit B (PDGFB)," exact="tumor" post="necrosis factor (TNF)-Î±, and vascular endothelial factor (VEGF)-A in"/>
 <result pre="growth factor subunit B (PDGFB), tumor necrosis factor (TNF)-Î±, and" exact="vascular" post="endothelial factor (VEGF)-A in the plasma of COVID-19 patients"/>
 <result pre="of the infected patients progress to stage 3, which involves" exact="viral" post="replication in the alveolar type II cells, pulmonary infiltration"/>
 <result pre="to stage 3, which involves viral replication in the alveolar" exact="type II" post="cells, pulmonary infiltration of immune cells leading to pathologic"/>
 <result pre="which involves viral replication in the alveolar type II cells," exact="pulmonary" post="infiltration of immune cells leading to pathologic changes associated"/>
 <result pre="cells leading to pathologic changes associated with severe pneumonia, and" exact="acute" post="respiratory distress syndrome (ARDS) with fatal outcome [14]. Widespread"/>
 <result pre="leading to pathologic changes associated with severe pneumonia, and acute" exact="respiratory" post="distress syndrome (ARDS) with fatal outcome [14]. Widespread damages"/>
 <result pre="pathologic changes associated with severe pneumonia, and acute respiratory distress" exact="syndrome" post="(ARDS) with fatal outcome [14]. Widespread damages in the"/>
 <result pre="with fatal outcome [14]. Widespread damages in the lungs include" exact="pulmonary" post="edema, diffuse alveolar damage with hyaline membranes, fibrosis, multinucleated"/>
 <result pre="outcome [14]. Widespread damages in the lungs include pulmonary edema," exact="diffuse" post="alveolar damage with hyaline membranes, fibrosis, multinucleated giant cells,"/>
 <result pre="the pneumocyte. Uncontrolled cytokine storm, as a product of the" exact="infiltrating" post="immune cells in the lungs, causes severe systemic inflammation,"/>
 <result pre="of the infiltrating immune cells in the lungs, causes severe" exact="systemic" post="inflammation, ARDS, multiorgan failure, and death [14]. Further, fatal"/>
 <result pre="elevated in the presence of comorbidities that include diabetes, hypertension," exact="chronic" post="obstructive pulmonary disease, asthma, cardiovascular disease, and cancer [16]."/>
 <result pre="the presence of comorbidities that include diabetes, hypertension, chronic obstructive" exact="pulmonary" post="disease, asthma, cardiovascular disease, and cancer [16]. The central"/>
 <result pre="comorbidities that include diabetes, hypertension, chronic obstructive pulmonary disease, asthma," exact="cardiovascular disease," post="and cancer [16]. The central immunopathogenic mechanism in COVID-19"/>
 <result pre="diabetes, hypertension, chronic obstructive pulmonary disease, asthma, cardiovascular disease, and" exact="cancer" post="[16]. The central immunopathogenic mechanism in COVID-19 associated complications"/>
 <result pre="mechanism in COVID-19 associated complications and morbidities is the cytokine" exact="syndrome" post="elicited by the unbridled inflammatory immune cells. Indeed, elevated"/>
 <result pre="chemokine (C-X-C motif) ligand 10 (CXCL10) correlated with severity of" exact="disease" post="[12] and negatively correlated with T cell counts [17,18]."/>
 <result pre="and GM-CSF have been reported in COVID-19 patients with severe" exact="pneumonia" post="[19]. While there is limited data available on the"/>
 <result pre="in COVID-19 patients with severe pneumonia [19]. While there is" exact="limited" post="data available on the role of NK cells in"/>
 <result pre="mice models were shown to be only semipermissive to SARS-CoV-1" exact="infection" post="since murine ACE2 binds less efficiently than human ACE2"/>
 <result pre="to infect lungs of wild type mice [23]. The poor" exact="viral" post="tropism was overcome by K18-hACE2 transgenic mice expressing human"/>
 <result pre="[24]. However, this model delivered an altered clinical and fatal" exact="disease" post="with 100% mortality and viral infiltration in the brain"/>
 <result pre="an altered clinical and fatal disease with 100% mortality and" exact="viral" post="infiltration in the brain of SARS-CoV-1â€&quot;infected mice [24], but"/>
 <result pre="fatal disease with 100% mortality and viral infiltration in the" exact="brain" post="of SARS-CoV-1â€&quot;infected mice [24], but no viral RNA or"/>
 <result pre="infiltration in the brain of SARS-CoV-1â€&quot;infected mice [24], but no" exact="viral" post="RNA or pathogenicity was observed in brains of SARS-CoV-2â€&quot;infected"/>
 <result pre="[23]. While ferrets are susceptible to SARSCoV2, only mild clinical" exact="disease" post="with high viral titers in upper respiratory tract and"/>
 <result pre="are susceptible to SARSCoV2, only mild clinical disease with high" exact="viral" post="titers in upper respiratory tract and relatively lower viral"/>
 <result pre="SARSCoV2, only mild clinical disease with high viral titers in" exact="upper" post="respiratory tract and relatively lower viral titers in lungs"/>
 <result pre="only mild clinical disease with high viral titers in upper" exact="respiratory" post="tract and relatively lower viral titers in lungs was"/>
 <result pre="with high viral titers in upper respiratory tract and relatively" exact="lower" post="viral titers in lungs was reported [25]. Shi and"/>
 <result pre="high viral titers in upper respiratory tract and relatively lower" exact="viral" post="titers in lungs was reported [25]. Shi and colleagues"/>
 <result pre="the brain, and other tissues, indicating that ferrets show only" exact="partial" post="recapitulation of human disease. Old World monkeys and humans"/>
 <result pre="ACE2 in NHP allows them to be more permissive for" exact="viral" post="replication. In addition, NHP are more comparable to humans"/>
 <result pre="than rodent models [28]. SARS-CoV2â€&quot;infected rhesus and cynomolgus macaques exhibited" exact="viral" post="shedding in nasopharyngeal and oral samples, pneumonia and lung"/>
 <result pre="cynomolgus macaques exhibited viral shedding in nasopharyngeal and oral samples," exact="pneumonia" post="and lung pathology characterized by diffuse alveolar damage (DAD),"/>
 <result pre="nasopharyngeal and oral samples, pneumonia and lung pathology characterized by" exact="diffuse" post="alveolar damage (DAD), pulmonary edema and hyaline membrane formation,"/>
 <result pre="pneumonia and lung pathology characterized by diffuse alveolar damage (DAD)," exact="pulmonary" post="edema and hyaline membrane formation, and accumulation of neutrophils,"/>
 <result pre="neutrophils, macrophages, and lymphocytes similar to COVID-19 patients [29â€&quot;31]. Prolonged" exact="viral" post="shedding and severe interstitial pneumonia was observed in aged"/>
 <result pre="to COVID-19 patients [29â€&quot;31]. Prolonged viral shedding and severe interstitial" exact="pneumonia" post="was observed in aged macaques but did not accompany"/>
 <result pre="observed in aged macaques but did not accompany changes in" exact="disease" post="outcome compared to young adults [30,32]. Neutralizing antibody development"/>
 <result pre="young adults [30,32]. Neutralizing antibody development and cellular immunity after" exact="primary" post="infection in rhesus macaques was found to protect against"/>
 <result pre="adults [30,32]. Neutralizing antibody development and cellular immunity after primary" exact="infection" post="in rhesus macaques was found to protect against reinfection"/>
 <result pre="addition to mice and rats and was capable of inducing" exact="complete" post="protection against challenge [14]. Overall, these studies show that"/>
 <result pre="studies show that animal models, particularly NHP, can recapitulate human" exact="viral" post="shedding, antiviral immune responses, and lung pathology; however, more"/>
 <result pre="effectively test vaccines and therapeutic interventions. NK cells in COVID-19" exact="disease" post="The role of NK cells in coronaviral infections has"/>
 <result pre="in COVID-19 disease The role of NK cells in coronaviral" exact="infections" post="has been mostly understudied because mice studies showed that"/>
 <result pre="studies showed that NK cells may not be essential for" exact="viral" post="clearance in SARS-CoV-1 and MERS-CoV infections. However, the recent"/>
 <result pre="in COVID-19 (Fig 1). In SARS-CoV-2â€&quot;infected patients, the frequency of" exact="peripheral" post="NK cells were reduced [17,18,20,34â€&quot;37] or not significantly altered"/>
 <result pre="patients reverted back to normal levels after recovery [37]. Functionally," exact="peripheral" post="NK cells and CD8 T cells exhibited reduced expression"/>
 <result pre="expression of CD107a, IFN-Î³, and TNF-Î± in COVID-19 patients [39]." exact="Elevated" post="NKG2A expression on both NK and T cells indicative"/>
 <result pre="on NK cells was found to be mediated by the" exact="viral" post="spike protein. In vitro coculture of peripheral NK cells"/>
 <result pre="mediated by the viral spike protein. In vitro coculture of" exact="peripheral" post="NK cells with SARS-CoV-2 spike protein transfected lung epithelial"/>
 <result pre="of peripheral NK cells with SARS-CoV-2 spike protein transfected lung" exact="epithelial" post="cells resulted in reduced NK degranulation and up-regulation of"/>
 <result pre="concomitant histocompatibility leukocyte antigen E (HLA-E) expression on the lung" exact="epithelial" post="cells shows that the spike protein could lead to"/>
 <result pre="patients have reduced frequencies of NK cells, T cells, and" exact="total" post="lymphocyte counts, while a high NLR is one of"/>
 <result pre="high NLR is one of the prognostic markers of poor" exact="disease" post="outcome [44]. In a study comparing patients with COVID-19"/>
 <result pre="[44]. In a study comparing patients with COVID-19 pneumonia, nonâ€&quot;COVID-19" exact="pneumonia" post="and healthy controls, Varchetta and colleagues [45] reported increased"/>
 <result pre="mediated cytotoxicity (ADCC) than healthy controls [45]. This study though" exact="limited" post="by a small sample size, provides promising data that"/>
 <result pre="NKG2C, perforin, and ksp (killer specific secretory protein)-37 correlated with" exact="disease" post="severity. Perforin expression of CD56bright NK cells positively correlated"/>
 <result pre="of CD56bright NK cells positively correlated with IL-6, Sequential Organ" exact="Failure" post="Assessment (SOFA) scores and neutrophil count and inversely correlated"/>
 <result pre="Assessment (SOFA) scores and neutrophil count and inversely correlated with" exact="partial" post="pressure of oxygen (PaO2) and fraction of inspired oxygen"/>
 <result pre="cells [48]. More significantly, the role of NK cell at" exact="primary" post="sites of infection, lungs, and other tissue would be"/>
 <result pre="subsets in the periphery. NK cells at sites of SARS-CoV-2" exact="infection" post="Lung NK cells account for approximately 10% to 20%"/>
 <result pre="include CD56dimCD16+ and CD57+NKG2A- NK cells than commonly observed in" exact="peripheral" post="blood mononuclear cells (PBMC) and other tissues [49,50], were"/>
 <result pre="the suppressive local microenvironment contributed by alveolar macrophages and the" exact="epithelial" post="lining [51], thus tightly regulating pulmonary homeostasis. When homeostasis"/>
 <result pre="alveolar macrophages and the epithelial lining [51], thus tightly regulating" exact="pulmonary" post="homeostasis. When homeostasis is disrupted during infections, the lung"/>
 <result pre="adaptive cells [52]. In addition, IL-22-producing NKp46+ NK cells facilitating" exact="epithelial" post="regeneration were found in bronchoalveolar lavage fluid (BALF), trachea,"/>
 <result pre="suggest that the hyporesponsive lung NK cells are activated in" exact="respiratory" post="infections and could lead to viral clearance and/or lung"/>
 <result pre="that the hyporesponsive lung NK cells are activated in respiratory" exact="infections" post="and could lead to viral clearance and/or lung pathology,"/>
 <result pre="cells are activated in respiratory infections and could lead to" exact="viral" post="clearance and/or lung pathology, depending on the dose of"/>
 <result pre="clearance and/or lung pathology, depending on the dose of the" exact="virus infection." post="In SARS-CoV-1 infected mice, immune cells including NK cells,"/>
 <result pre="NK cells and their ADCC functions are not essential for" exact="viral" post="clearance in the lungs [56â€&quot;58]. However, rodent respiratory system"/>
 <result pre="essential for viral clearance in the lungs [56â€&quot;58]. However, rodent" exact="respiratory" post="system do not recapitulate human lung immunology efficiently. NHP"/>
 <result pre="found in several tissues associated with the gastrointestinal (GI) tract," exact="cardiovascular" post="system, and brain. ACE2 is particularly enriched in the"/>
 <result pre="as nausea, vomiting, and diarrhea, are also associated with SARS-CoV-2" exact="infection" post="with viral shedding in fecal samples [60, 61]. NK"/>
 <result pre="vomiting, and diarrhea, are also associated with SARS-CoV-2 infection with" exact="viral" post="shedding in fecal samples [60, 61]. NK cells are"/>
 <result pre="NK cells are present in large and small intestine and" exact="localized" post="in the intraepithelial lymphocyte compartment, lamina propria, and Peyerâ€™s"/>
 <result pre="cell subsets have been reported in mucosal infections, particularly in" exact="HIV infection," post="there are no studies to provide information on coronavirus-mediated"/>
 <result pre="or pathology in the gut of humans and animal models." exact="Neurologic" post="manifestations including taste, smell, and/or vison impairment, acute cerebrovascular"/>
 <result pre="animal models. Neurologic manifestations including taste, smell, and/or vison impairment," exact="acute" post="cerebrovascular diseases, and impaired consciousness are increasingly reported in"/>
 <result pre="are increasingly reported in COVID-19 patients, particularly those with severe" exact="respiratory" post="involvement and lymphocytopenia [63â€&quot;66]. It is not yet clear"/>
 <result pre="if the neurological symptoms are due to the posited cytokine" exact="syndrome" post="or the direct CNS invasion of the SARS-CoV-2 virus."/>
 <result pre="virus. In transgenic mice expressing human ACE2, SARS-CoV-1 entered the" exact="brain" post="through the olfactory nerve, rapidly replicated in the brain,"/>
 <result pre="but, surprisingly, there was no evidence of inflammation in the" exact="brain" post="[67]. The fatal outcome of brain infection in this"/>
 <result pre="of inflammation in the brain [67]. The fatal outcome of" exact="brain" post="infection in this model could be attributed to any"/>
 <result pre="inflammation in the brain [67]. The fatal outcome of brain" exact="infection" post="in this model could be attributed to any of"/>
 <result pre="model could be attributed to any of these several mechanisms:" exact="neuronal" post="infection and dropout, infection of the cardiorespiratory center in"/>
 <result pre="could be attributed to any of these several mechanisms: neuronal" exact="infection" post="and dropout, infection of the cardiorespiratory center in the"/>
 <result pre="to any of these several mechanisms: neuronal infection and dropout," exact="infection" post="of the cardiorespiratory center in the medulla, and cytokine"/>
 <result pre="of the key immune cells that can cross the blood" exact="brain" post="barrier under pathological conditions. Indeed, NK cells were the"/>
 <result pre="the major immune cells elevated in patients with disrupted blood" exact="brain" post="barrier and were correlated with multiple proinflammatory cytokines and"/>
 <result pre="CCL3, and IL-6, in the cerebrospinal fluid of patients with" exact="neuroinflammation" post="[68]. In mice infected with a recombinant murine coronavirus,"/>
 <result pre="[68]. In mice infected with a recombinant murine coronavirus, mouse" exact="hepatitis" post="virus (MHV) expressing CXCL10, showed CXCL10 mediated recruitment of"/>
 <result pre="CXCL10, showed CXCL10 mediated recruitment of NK cells into the" exact="brain" post="and was critical in controlling MHV infection before T"/>
 <result pre="cells into the brain and was critical in controlling MHV" exact="infection" post="before T cell responses were activated in the brain"/>
 <result pre="MHV infection before T cell responses were activated in the" exact="brain" post="[69]. These studies indicate the NK cells are recruited"/>
 <result pre="during inflammation and could have potential neuroprotective roles against infections." exact="Limited" post="NK cell research exists in other major organs such"/>
 <result pre="and/or tissue injury in the inflammatory pathogenesis of renal and" exact="cardiovascular" post="diseases. While the peripheral immune responses and parameters are"/>
 <result pre="the inflammatory pathogenesis of renal and cardiovascular diseases. While the" exact="peripheral" post="immune responses and parameters are useful in generating disease"/>
 <result pre="the peripheral immune responses and parameters are useful in generating" exact="disease" post="outcome predictors for COVID-19, knowledge of immune cell responses"/>
 <result pre="local and mucosal tissue microenvironment are even more critical for" exact="viral" post="control and limiting severity of disease. The lack of"/>
 <result pre="cell knowledge and in general early immune responses at the" exact="primary" post="site of infection and the lungs in coronaviral infections"/>
 <result pre="in general early immune responses at the primary site of" exact="infection" post="and the lungs in coronaviral infections in both humans"/>
 <result pre="the primary site of infection and the lungs in coronaviral" exact="infections" post="in both humans and animal models is a huge"/>
 <result pre="NK cellâ€&quot;based intervention in COVID-19 Since the outbreak of COVID-19" exact="infections" post="worldwide began around January 2020, there has been a"/>
 <result pre="of infection, could prove useful against COVID-19 since an early" exact="viral" post="clearance would limit the development of cytokine storm and"/>
 <result pre="the role of BCG vaccination in the reduction of COVID-19" exact="infections" post="and mortality [72â€&quot;74]. The hypothesis is based on observational"/>
 <result pre="vivo expansion of NK cells more than 10-fold while their" exact="tumor" post="killing functions remained the same under normoxia and hypoxia"/>
 <result pre="their tumor killing functions remained the same under normoxia and" exact="hypoxia" post="[77]. A clinical trial to study the efficacy of"/>
 <result pre="efficacy of vitamin C infusion for COVID-19 patients with severe" exact="pneumonia" post="is also underway in China [78] (NCT04264533). Functional exhaustion"/>
 <result pre="placental CD34+ cells and is being tested for the treatment" exact="acute" post="myeloid leukemia and multiple myeloma. Recently, the Food and"/>
 <result pre="CD34+ cells and is being tested for the treatment acute" exact="myeloid leukemia" post="and multiple myeloma. Recently, the Food and Drug Administration"/>
 <result pre="cells and is being tested for the treatment acute myeloid" exact="leukemia" post="and multiple myeloma. Recently, the Food and Drug Administration"/>
 <result pre="is being tested for the treatment acute myeloid leukemia and" exact="multiple myeloma." post="Recently, the Food and Drug Administration (FDA) has approved"/>
 <result pre="therapeutic approaches include convalescent serum and neutralizing antibody for thwarting" exact="viral" post="infections. Several biotech/pharmaceutical companies, including Regeneron, AbCellera and Lily,"/>
 <result pre="technologies against SARS-CoV-2 [84]. In addition to their roles in" exact="viral" post="neutralization, the antibody-based therapeutics could also mediate effector functions"/>
 <result pre="that phagocytosis by macrophages was the major causative factor in" exact="viral" post="clearance from lungs. Leronlimab that targets chemokine receptor CCR5"/>
 <result pre="receptor CCR5 was originally developed to block HIV binding and" exact="breast cancer" post="metastasis and is now being tested for COVID-19 therapy"/>
 <result pre="CCR5 was originally developed to block HIV binding and breast" exact="cancer" post="metastasis and is now being tested for COVID-19 therapy"/>
 <result pre="was originally developed to block HIV binding and breast cancer" exact="metastasis" post="and is now being tested for COVID-19 therapy (NCT04347239)."/>
 <result pre="with antibody therapy is the potential to develop antibody enhanced" exact="disease" post="(ADE) as seen in dengue and vaccine induced ADE"/>
 <result pre="seen in dengue and vaccine induced ADE in RSV and" exact="atypical" post="measles (reviewed in [85]). While, our current knowledge in"/>
 <result pre="in dengue and vaccine induced ADE in RSV and atypical" exact="measles" post="(reviewed in [85]). While, our current knowledge in human"/>
 <result pre="of the NK cell therapy and the severity of the" exact="disease" post="status need to be considered to tip the balance"/>
 <result pre="NK cell responses would be more effective early in the" exact="infection" post="and would prevent progression of the disease. Immunomodulation of"/>
 <result pre="[86]. A randomized Phase II trial in Hong Kong showed" exact="viral" post="clearance in patients with mild and moderate COVID-19 when"/>
 <result pre="on myeloid cells, neutralizing antibodies, and T cells in SARS-CoV-2" exact="infection" post="while an important antiviral defense system, the NK cells,"/>
 <result pre="cells, remain understudied. The role of NK cells in other" exact="viral" post="infections and tumors have been well established that NK"/>
 <result pre="remain understudied. The role of NK cells in other viral" exact="infections" post="and tumors have been well established that NK cellâ€&quot;based"/>
 <result pre="such as the type of therapy, timing of therapeutic interventions," exact="disease" post="severity and associated comorbidities, will ultimately influence whether NK"/>
 <result pre="ChenYM, WangW, SongZG, et al.A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature. 2020;579(7798):265â€&quot;9. Epub 2020/02/06. 10.1038/s41586-020-2008-332015508 2SuS,"/>
 <result pre="WangW, SongZG, et al.A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature. 2020;579(7798):265â€&quot;9. Epub 2020/02/06. 10.1038/s41586-020-2008-332015508 2SuS, WongG,"/>
 <result pre="LiX, YangB, SongJ, et al.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019. N Engl J Med. 2020;382(8):727â€&quot;33. Epub"/>
 <result pre="2020/04/14. 10.1016/j.jpha.2020.03.00132282863 6RothanHA, ByrareddySN. The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreak. J Autoimmun. 2020;109:102433 Epub 2020/03/03. 10.1016/j.jaut.2020.10243332113704 7MasonRJ."/>
 <result pre="10.1016/j.cell.2020.02.05232142651 9DingQ, LuP, FanY, XiaY, LiuM. The clinical characteristics of" exact="pneumonia" post="patients coinfected with 2019 novel coronavirus and influenza virus"/>
 <result pre="al.Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, China. JAMA. 2020 Epub 2020/02/08. 10.1001/jama.2020.158532031570 11HuangC,"/>
 <result pre="ZhangX, GuoL, et al.Relationships among lymphocyte subsets, cytokines, and the" exact="pulmonary" post="inflammation index in coronavirus (COVID-19) infected patients. Br J"/>
 <result pre="and Functional Exhaustion of T Cells in Patients With Coronavirus" exact="Disease" post="2019 (COVID-19). Front Immunol. 2020;11:827 Epub 2020/05/20. 10.3389/fimmu.2020.0082732425950 19ZhouY"/>
 <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus. BioRxiv. 2020 Epub"/>
 <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus. BioRxiv. 2020 Epub 02/20/2020."/>
 <result pre="GreenoughTC, MooreMJ, VasilievaN, SomasundaranM, SullivanJL, et al.Efficient replication of severe" exact="acute" post="respiratory syndrome coronavirus in mouse cells is limited by"/>
 <result pre="MooreMJ, VasilievaN, SomasundaranM, SullivanJL, et al.Efficient replication of severe acute" exact="respiratory" post="syndrome coronavirus in mouse cells is limited by murine"/>
 <result pre="VasilievaN, SomasundaranM, SullivanJL, et al.Efficient replication of severe acute respiratory" exact="syndrome" post="coronavirus in mouse cells is limited by murine angiotensin-converting"/>
 <result pre="of severe acute respiratory syndrome coronavirus in mouse cells is" exact="limited" post="by murine angiotensin-converting enzyme 2. J Virol. 2004;78(20):11429â€&quot;33. Epub"/>
 <result pre="10.1038/s41586-020-2312-y .32380511 24McCrayPBJr., Pewe, Wohlford-LenaneC, HickeyM, ManzelL, ShiL, et al.Lethal" exact="infection" post="of K18-hACE2 mice infected with severe acute respiratory syndrome"/>
 <result pre="ShiL, et al.Lethal infection of K18-hACE2 mice infected with severe" exact="acute" post="respiratory syndrome coronavirus. J Virol. 2007;81(2):813â€&quot;21. Epub 2006/11/03. 10.1128/JVI.02012-0617079315"/>
 <result pre="et al.Lethal infection of K18-hACE2 mice infected with severe acute" exact="respiratory" post="syndrome coronavirus. J Virol. 2007;81(2):813â€&quot;21. Epub 2006/11/03. 10.1128/JVI.02012-0617079315 25KimYI,"/>
 <result pre="al.Lethal infection of K18-hACE2 mice infected with severe acute respiratory" exact="syndrome" post="coronavirus. J Virol. 2007;81(2):813â€&quot;21. Epub 2006/11/03. 10.1128/JVI.02012-0617079315 25KimYI, KimSG,"/>
 <result pre="2020/06/09. 10.1101/2020.04.09.03496732511330 28MillerLA, RoyerCM, PinkertonKE, SchelegleES. Nonhuman Primate Models of" exact="Respiratory" post="Disease: Past, Present, and Future. ILAR J. 2017;58(2):269â€&quot;80. Epub"/>
 <result pre="ILAR J. 2017;58(2):269â€&quot;80. Epub 2017/12/08. 10.1093/ilar/ilx03029216343 29MunsterVJ, de WitE, FeldmannH." exact="Pneumonia" post="from human coronavirus in a macaque model. N Engl"/>
 <result pre="2020/04/19. 10.1126/science.abb731432303590 31ChandrashekarA, LiuJ, MartinotAJ, McMahanK, MercadoNB, PeterL, et al.SARS-CoV-2" exact="infection" post="protects against rechallenge in rhesus macaques. Science. 2020 Epub"/>
 <result pre="pathway. 202010.21203/rs.3.rs-31860/v1 35Giamarellos-BourboulisEJ, NeteaMG, RovinaN, AkinosoglouK, AntoniadouA, AntonakosN, et al.Complex" exact="Immune Dysregulation" post="in COVID-19 Patients with Severe Respiratory Failure. Cell Host"/>
 <result pre="AntoniadouA, AntonakosN, et al.Complex Immune Dysregulation in COVID-19 Patients with" exact="Severe" post="Respiratory Failure. Cell Host Microbe. 2020 Epub 2020/04/23. 10.1016/j.chom.2020.04.00932320677"/>
 <result pre="AntonakosN, et al.Complex Immune Dysregulation in COVID-19 Patients with Severe" exact="Respiratory" post="Failure. Cell Host Microbe. 2020 Epub 2020/04/23. 10.1016/j.chom.2020.04.00932320677 36WenW,"/>
 <result pre="al.Longitudinal characteristics of lymphocyte responses and cytokine profiles in the" exact="peripheral" post="blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763 Epub 2020/05/04."/>
 <result pre="exhaustion levels and reduced functional diversity of T cells in" exact="peripheral" post="blood may predict severe progression in COVID-19 patients. Cell"/>
 <result pre="2020/05/10. 10.1038/s41423-020-0450-732382127 41NandiB, BeharSM. Regulation of neutrophils by interferon-gamma limits" exact="lung inflammation" post="during tuberculosis infection. J Exp Med. 2011;208(11):2251â€&quot;62. Epub 2011/10/05."/>
 <result pre="BeharSM. Regulation of neutrophils by interferon-gamma limits lung inflammation during" exact="tuberculosis" post="infection. J Exp Med. 2011;208(11):2251â€&quot;62. Epub 2011/10/05. 10.1084/jem.2011091921967766 42WuJ,"/>
 <result pre="function of NK cells via the STAT3 pathway in oesophageal" exact="squamous cell carcinoma." post="J Exp Clin Cancer Res. 2019;38(1):321 Epub 2019/07/22. 10.1186/s13046-019-1310-031324197"/>
 <result pre="STAT3 pathway in oesophageal squamous cell carcinoma. J Exp Clin" exact="Cancer" post="Res. 2019;38(1):321 Epub 2019/07/22. 10.1186/s13046-019-1310-031324197 43HashizumeM, HiguchiY, UchiyamaY, MiharaM."/>
 <result pre="ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus" exact="disease" post="2019 (COVID-19): A meta-analysis. J Med Virol. 2020 Epub"/>
 <result pre="OlvieroB, MantovaniS, LudovisiS, CerinoA, VecchiaM, RodaS, SachsM, BrunoR, MondelliMU. Unique" exact="Immunological" post="Profile in Patients with COVID-19. Nat Immunol. 2020 Epub"/>
 <result pre="edge sword against SARS-CoV-2. Advances in Biological Regulation. 2020;77. PubMed" exact="Central" post="PMCID: PMC7292949. 49MarquardtN, KekalainenE, ChenP, KvedaraiteE, WilsonJN, IvarssonMA, et"/>
 <result pre="Lung natural killer cells in mice: phenotype and response to" exact="respiratory" post="infection. Immunology. 2012;137(1):37â€&quot;47. Epub 2012/05/23. 10.1111/j.1365-2567.2012.03607.x22612500 51RobinsonBW, PinkstonP, CrystalRG."/>
 <result pre="lung: surface phenotype, target preference, and response to local influenza" exact="virus infection." post="J Immunol. 1983;131(6):2699â€&quot;704. Epub 1983/12/01. .6644021 53KumarP, ThakarMS, OuyangW,"/>
 <result pre="53KumarP, ThakarMS, OuyangW, MalarkannanS. IL-22 from conventional NK cells is" exact="epithelial" post="regenerative and inflammation protective during influenza infection. Mucosal Immunol."/>
 <result pre="cells is epithelial regenerative and inflammation protective during influenza infection." exact="Mucosal" post="Immunol. 2013;6(1):69â€&quot;82. Epub 2012/06/29. 10.1038/mi.2012.4922739232 54ZhouG, JuangSW, KaneKP. NK"/>
 <result pre="54ZhouG, JuangSW, KaneKP. NK cells exacerbate the pathology of influenza" exact="virus infection" post="in mice. Eur J Immunol. 2013;43(4):929â€&quot;38. Epub 2013/02/26. 10.1002/eji.201242620"/>
 <result pre="JuangSW, KaneKP. NK cells exacerbate the pathology of influenza virus" exact="infection" post="in mice. Eur J Immunol. 2013;43(4):929â€&quot;38. Epub 2013/02/26. 10.1002/eji.201242620"/>
 <result pre="LamirandeEW, PaddockCD, BartlettJH, ZakiSR, et al.Cellular immune responses to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice:"/>
 <result pre="PaddockCD, BartlettJH, ZakiSR, et al.Cellular immune responses to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+"/>
 <result pre="BartlettJH, ZakiSR, et al.Cellular immune responses to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T"/>
 <result pre="al.Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
 <result pre="et al.Rapid generation of a mouse model for Middle East" exact="respiratory" post="syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970â€&quot;5."/>
 <result pre="57GlassWG, SubbaraoK, MurphyB, MurphyPM. Mechanisms of host defense following severe" exact="acute" post="respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol."/>
 <result pre="SubbaraoK, MurphyB, MurphyPM. Mechanisms of host defense following severe acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol. 2004;173(6):4030â€&quot;9."/>
 <result pre="Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV)" exact="pulmonary" post="infection of mice. J Immunol. 2004;173(6):4030â€&quot;9. Epub 2004/09/10. 10.4049/jimmunol.173.6.4030"/>
 <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of mice. J Immunol. 2004;173(6):4030â€&quot;9. Epub 2004/09/10. 10.4049/jimmunol.173.6.4030 .15356152"/>
 <result pre="gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and" exact="disease" post="recurrence in COVID-19 patients. 202010.1101/2020.04.14.040204 61GuJ HB, WangJ. COVID-19:"/>
 <result pre=".12891535 63MunzM, WessendorfS, KoretsisG, TewaldF, BaegiR, KramerS, et al.Acute transverse" exact="myelitis" post="after COVID-19 pneumonia. J Neurol. 2020;267(8):2196â€&quot;7. Epub 2020/05/28. 10.1007/s00415-020-09934-w32458198"/>
 <result pre="ChenS, HeQ, et al.Neurologic Manifestations of Hospitalized Patients With Coronavirus" exact="Disease" post="2019 in Wuhan, China. JAMA Neurol. 2020 Epub 2020/04/11."/>
 <result pre="Hailing and Li, Man and Jin, Huijuan and Hu, Bo." exact="Acute" post="Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational"/>
 <result pre="and Li, Man and Jin, Huijuan and Hu, Bo. Acute" exact="Cerebrovascular" post="Disease Following COVID-19: A Single Center, Retrospective, Observational Study"/>
 <result pre="Li, Man and Jin, Huijuan and Hu, Bo. Acute Cerebrovascular" exact="Disease" post="Following COVID-19: A Single Center, Retrospective, Observational Study (3/3/2020)."/>
 <result pre="neuroinvasive potential of SARS-CoV2 may play a role in the" exact="respiratory" post="failure of COVID-19 patients. J Med Virol. 2020 Epub"/>
 <result pre="2020 Epub 2020/02/28. 10.1002/jmv.25728 .32104915 67NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanS." exact="Severe" post="acute respiratory syndrome coronavirus infection causes neuronal death in"/>
 <result pre="Epub 2020/02/28. 10.1002/jmv.25728 .32104915 67NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanS. Severe" exact="acute" post="respiratory syndrome coronavirus infection causes neuronal death in the"/>
 <result pre="2020/02/28. 10.1002/jmv.25728 .32104915 67NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanS. Severe acute" exact="respiratory" post="syndrome coronavirus infection causes neuronal death in the absence"/>
 <result pre="10.1002/jmv.25728 .32104915 67NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanS. Severe acute respiratory" exact="syndrome" post="coronavirus infection causes neuronal death in the absence of"/>
 <result pre="67NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanS. Severe acute respiratory syndrome coronavirus" exact="infection" post="causes neuronal death in the absence of encephalitis in"/>
 <result pre="MooreS, CassellM, PerlmanS. Severe acute respiratory syndrome coronavirus infection causes" exact="neuronal" post="death in the absence of encephalitis in mice transgenic"/>
 <result pre="acute respiratory syndrome coronavirus infection causes neuronal death in the" exact="absence of" post="encephalitis in mice transgenic for human ACE2. J Virol."/>
 <result pre="syndrome coronavirus infection causes neuronal death in the absence of" exact="encephalitis" post="in mice transgenic for human ACE2. J Virol. 2008;82(15):7264â€&quot;75."/>
 <result pre="StilesLN, HurstKR, HardisonJL, ManningJE, et al.CXC chemokine ligand 10 controls" exact="viral infection" post="in the central nervous system: evidence for a role"/>
 <result pre="HurstKR, HardisonJL, ManningJE, et al.CXC chemokine ligand 10 controls viral" exact="infection" post="in the central nervous system: evidence for a role"/>
 <result pre="of Natural Killer T Cells and Natural Killer Cells in" exact="Kidney" post="Injury. Int J Mol Sci. 2019;20(10). Epub 2019/05/30. 10.3390/ijms2010248731137499"/>
 <result pre="2019/05/30. 10.3390/ijms2010248731137499 71OngS, RoseNR, CihakovaD. Natural killer cells in inflammatory" exact="heart" post="disease. Clin Immunol. 2017;175:26â€&quot;33. Epub 2016/11/30. 10.1016/j.clim.2016.11.01027894980 72HegartyPK, SfakianosJP,"/>
 <result pre="2020/04/29. 10.1016/j.mehy.2020.10977732344314 80DaherM, RezvaniK. Next generation natural killer cells for" exact="cancer" post="immunotherapy: the promise of genetic engineering. Curr Opin Immunol."/>
 <result pre="10.1016/j.coi.2018.03.01329605760 81RezvaniK, RouceR, LiuE, ShpallE. Engineering Natural Killer Cells for" exact="Cancer" post="Immunotherapy. Mol Ther. 2017;25(8):1769â€&quot;81. Epub 2017/07/03. 10.1016/j.ymthe.2017.06.01228668320 82LiuE, MarinD,"/>
 <result pre="BasarR, et al.Use of CAR-Transduced Natural Killer Cells in CD19-Positive" exact="Lymphoid" post="Tumors. N Engl J Med. 2020;382(6):545â€&quot;53. Epub 2020/02/06. 10.1056/NEJMoa191060732023374"/>
 <result pre="al.The Promise and Peril of Natural Killer Cell Therapies in" exact="Pulmonary" post="Infection. Immunity. 2020;52(6):887â€&quot;9. Epub 2020/05/15. 10.1016/j.immuni.2020.04.01832405233 84Lowe D. Monoclonal"/>
 <result pre="therapy and vaccine development. EBioMedicine. 2020 Epub 04/16/2020. 10.1016/j.ebiom.2020.102768 PubMed" exact="Central" post="PMCID: PMC7161485. 32344202 86GrossCC, Schulte-MecklenbeckA, WiendlH, MarcenaroE, Kerlero de"/>
 <result pre="RosboN, UccelliA, et al.Regulatory Functions of Natural Killer Cells in" exact="Multiple" post="Sclerosis. Front Immunol. 2016;7:606 Epub 2017/01/10. 10.3389/fimmu.2016.0060628066417 87HungIFN, LungKC,"/>
</results>
